Peptide receptor radionuclide therapy for neuroendocrine tumours

The Lancet Oncology in conversation with

English - September 05, 2020 08:00 - 19 minutes - 13.5 MB - ★★★★★ - 1 rating
Medicine Health & Fitness Education cancer radiotherapy chemotherapy mrna Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Larotrectinib in patients with TRK fusion-positive solid tumours

Next Episode: Adjuvant radiotherapy versus early salvage radiotherapy in prostate cancer

Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses the Review in The Lancet Oncology on molecular profiling of neuroendocrine tumours to predict response to peptide receptor radionuclide therapy.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv